A salt of an HMG-CoA reductase inhibitor with an amine, characterized in that said salt is an intermediate or a starting substance in a process for preparing the HMG-CoA reductase inhibitors and that said amine is selected from the group consisting of amines of the following formulae I and II;
- wherein:
- a1) R1, R2, R3 and R4 independently denote:
- a hydrogen atom;
- a straight or a branched alkyl group having 1 to 8 carbon atoms;
- a cycloalkyl group having 3 to 8 carbon atoms;
- an arylalkyl group wherein the alkyl group is methyl or ethyl and the aryl group is phenyl, which is optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;
- an arylalkyl group which is optionally substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms;
- a hydroxyalkyl group having 2 to 4 carbon atoms;
- or an aminoalkyl group having 2 to 4 carbon atoms, which are optionally substituted by an N-alkyl or N,N-dialkyl group wherein the alkyl group is alkyl having 1 to 4 carbon atoms;
- X denotes a hydrogen atom, a hydroxyl group, a halogen or a methyl group;
- m and n independently denote an integer from 0 to 5;
- or
- a2) NR1R2 or NR3R4 denote a heterocyclic ring having 3 to 7 methylene groups, one of these groups being optionally substituted by an oxygen or a sulfur atom or an imine group;
- and X, m and n are the same as defined above;
- wherein:
- b1) R′1, R′2, and R′3 are the same or different and denote hydrogen, alkyl, alkenyl, amine or hydroxy- or alkoxy-substituted alkyl or alkenyl, or substituted amino-alkyl or alkenyl, wherein the amino group is substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, provided that R′1, R′2 and R′3 are not hydrogen at the same time;
- or
- b2) R′1 and R′2, and optionally R′3, together with the nitrogen atom form a heterocyclic ring system including the nitrogen atom as a ring member, and optionally including an additional hetero atom, and if R′3 is not part of the ring system it is independently selected from hydrogen, alky, alkenyl, amino- or hydroxy or alkoxy-substituted alky, or substituted amino-alkyl wherein the amino group is substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms;
- or
- b3) R′1 is a group of general formula III,
- R′—(CHR′4)m— III
- wherein m is zero or an integer from 1 to 5, R′ is an aliphatic hydrocarbon cyclic system having 3 to 8 carbon atoms in the ring, optionally substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, R′4 is hydrogen, alkyl, amino- or hydroxy- or alkoxy-substituted alkyl, substituted amino-alkyl or alkenyl, wherein the amino group is substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, or a group of the same general formula as R′1 as defined herein above;
- R′2 and R′3 are the same as R′1 or hydrogen, alkyl, alkenyl, amino- or hydroxy- or alkoxy-substituted alkyl, or substituted amino-alkyl wherein the amino group is substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, or alkenyl;
- or
- b4) R′1 is an optionally substituted aryl group of general formula IV:
- wherein R′5 is hydrogen or one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, and m is zero or an integer from 1 to 5;
- and R′2 and R′3 may be independently hydrogen, alkyl, amino- or hydroxy- or alkoxy-substituted alkyl, or substituted amino-alkyl wherein the amino group is substituted by one or more substituents selected from the group consisting of a halogen, a hydroxyl group, an alkyl having 1 to 4 carbon atoms, an alkoxyl having 1 to 4 carbon atoms, an acyloxyl having 1 to 4 carbon atoms or an esterified carboxyl having 1 to 4 carbon atoms, or groups of the same general formula R′1;
- provided that
- when the HMG-CoA reductase inhibitor is lovastatin, the amine is not tetramethylamine or ethylenedianine,
- when the HMG-CoA reductase inhibitor is tetrahydro-M4 or tetrahydro-IsoM-4, the amine is not octylamine, 2-ethylhexylamine, benzylamine, α-methyl-benzylamine, phenethyline, dibenzylamine, N-methylbenzylamine, N,N-dimethylbenzylanine, N,N-diethylbenzylamine, N-ethyl-N-methylbenzylamine, tribenzylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, N-methylcyclopentylamine, N-ethylcyclohexylamine, N-ethylcycloheptylamine, dicyclohexylamine, N,N-dimethylcyclopentylamine, N,N-dimethylcyclohexylamine, N,N-diethylcyclobeptylamine, pyrrolidine, N-methylpyrrolidine, piperidine, N-methylpiperidine or morpholine;
- and
- when the HMG-CoA reductase inhibitor is the octahydronaphthalene oxime derivative of ML-236A, ML-236B, MB-530A or MB-530B, the amine is not t-octylamine, dibenzylamine, dicyclohexylamine or morpholine.